#United States #Chicago #cancer detection #Harbinger Health #RESOLVE™

Harbinger Health Reveals Groundbreaking Clinical Data on RESOLVE™ at ASCO 2026

Harbinger Health, a cutting-edge biotechnology firm dedicated to revolutionizing cancer detection, recently showcased significant clinical findings related to its RESOLVE™ platform at the ASCO Annual Meeting held in Chicago, Illinois. This revolutionary blood-based test aims to fill the critical gap that often exists between the suspicion of cancer and a confirmed diagnosis.

The data presented derive from the CORE-HH study, a prospective clinical trial analyzing patients who showed signs suggestive of cancer but had inconclusive imaging results. This study reflects real-world scenarios where patients experience uncertainty about their diagnosis, allowing RESOLVE™ to shine as a beacon of hope for timely cancer detection.

Key Findings from the CORE-HH Study

The CORE-HH study involved a sample of 209 adults aged 45 to 79, out of which 155 participants had been diagnosed with cancer, while the remaining 54 were found not to have the disease. Critical conditions analyzed included pulmonary nodules, liver lesions, and unexplained lymphadenopathy, which often lead to distressing delays in proper diagnosis and treatment.

Impressively, the RESOLVE™ test yielded a positive result in 54.8% of the confirmed cancer cases, translating to a positive likelihood ratio of 29.6. This figure emphasizes the test's capacity to significantly elevate the probability of cancer diagnosis in clinically suspicious cases.

Moreover, the test exhibited a remarkably low false-positive rate, with only one false-positive reported among the 54 individuals without cancer. These findings underscore the assay's reliability and potential to provide precise cancer assessments.

With a positive result, the probability of a confirmed cancer diagnosis escalated from 74.2% to a staggering 98.8%, effectively offering patients and clinicians much-needed confidence during critical decision-making periods.

Expert Insights on Diagnostic Uncertainty

Dr. Ajit Singh, CEO of Harbinger Health, expressed enthusiasm regarding the results from the symptomatic subgroup of the CORE-HH trial, emphasizing how they validate the practical use of RESOLVE™ in clinical scenarios fraught with uncertainty. He remarked on the anxiety that can arise during the prolonged wait for a definitive diagnosis and the adverse effects such delays can have on patient outcomes.

Alongside Dr. Singh, Dr. Luke R. G. Pike, a leading oncologist at Memorial Sloan Kettering Cancer Center and principal investigator for both the CORE-HH and PROCARES trials, underscored the implications of possessing a highly predictive blood test. Such innovations are pivotal in helping clinicians navigate complex diagnostic pathways, minimizing the need for invasive procedures that often accompany indecisiveness in diagnostics.

Ongoing Research and Future Prospects

To further validate these encouraging findings, Harbinger Health has initiated PROCARES, an ongoing multicenter observational study specifically designed to enroll this patient population. Results from PROCARES are projected to enhance the understanding and trust in RESOLVE™'s diagnostic capabilities, potentially paving the way for its commercial launch later this year.

Conclusion

As Harbinger Health continues to make strides in cancer detection technology, the RESOLVE™ platform represents a promising step towards addressing the challenges surrounding cancer diagnostics. With an innovative approach that leverages artificial intelligence combined with empirical insights into cancer biology, Harbinger is set to transform how clinicians and patients approach cancer suspicion and resolution.

For more information on RESOLVE™ and Harbinger Health’s initiatives, please visit Harbinger-Health.com and follow them on LinkedIn.